That is very important, because the way a protein in the body folds determines if a pharmaceutical will be able to bind to that protein and work. In other words, we need to understand how these proteins fold if we want a drug to work. Historically, this has actually been an experimental procedure (jeff brown investment prediction). Now, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to develop drugs that do what they're created to do. This was a breakthrough practically nobody observed. But it's going to have profound implications for curing illness. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be lots of financial investment chances in this area, too. Moving topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (future report review). That said, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be surprised if it pulled back maybe substantially prior to going higher - white house. I've been covering bitcoin for a long period of time now. One of the very first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial suggestion, I entitled my report "What's the Big Deal With Bitcoin?" That reveals you where the conversation was at the time. We were mostly informing readers. But that's not the huge question any longer. Now we're seeing institutional cash finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. Mass, Mutual is a relied on 170-year-old institution. So consider that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
And that's a big reason I'm bullish on it this year. jeff brown genome sequencing. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I anticipate 2021 will be another record year in IPOs. There are so lots of fantastic private business on the edge of striking the public markets And I've been working on a new way for you to invest even before these business go public.
This opportunity has actually been constructing over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to discover out all the information. Go right here to schedule your spot free of charge.
Emma Walsh here, managing editor of the Journal. Routine Journal readers know that tech isn't our typical beat (jeff brown market predictions). And when it comes to tech investing, we leave it to the professionals. Thankfully, we have several such professionals in our Rolodex. Our colleague Jeff Brown will be familiar to our long time readers. He is among the most accomplished tech investing professionals we understand (brownstone research). In fact, he had numerous triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to take a look at the huge picture and forecast what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and far more. These patterns are experiencing exponential development and creating unbelievable chances for financiers. I desire to make certain all our readers are prepared for what's next. And with that in mind, let me draw the picture of what I see coming in the next 12 months Our brand-new 5G (fifth-generation) wireless networks are a topic I have actually been covering for years now. jeff brown biotech picks. However regardless of what numerous readers might think, this is a pattern that's just starting. Although the COVID-19 pandemic interfered with supply chains last year, an impressive 250 million 5G-enabled devices were still offered.
And all of this ultimately resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (jeff brown biotech picks). Losing 2 months of production and sales actually affects the number of 5G devices are sold in the fiscal year. When you consider all of that, selling 250 million units is remarkable. More importantly, the delays brought on by the pandemic created a lots of bottled-up need. Which demand is now going to be pushed into 2021. In reality, I predict that more than 500 million 5G devices will be shipped in 2021 - jeff brown biotech stock pick for 2020. Which's not my only 5G prediction When I have actually discussed 5G in the past, I've described its three various stages.
In Stage 2, 5G devices go on sale. 5G phones and other products begin to reach consumers. And in Phase 3, 5G services start to be offered (jeff brown stock market prediction). That's when we start to see applications operating on 5G networks. Consider things like massive multiplayer video games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Stage 3 by this summer. This starts something of a virtuous cycle: The majority of people don't really care about the innovation. However they will care if there are amazing applications that can only be accessed with a 5G phone.
That leads to more 5G apps being developed. In reality, 5G is going to open up a suite of incredible applications: self-driving cars and trucks, the Internet of Things, robotic surgery, and more. All of these technologies need 5G. The investment opportunities going forward will be enormous. Stepping far from 5G, the next essential innovation I predict in 2021 is CRISPR genetic modifying. CRISPR means "clustered frequently interspaced brief palindromic repeat." It's a mouthful. But it's one of the most exciting developments in biotechnology. At a high level, CRISPR is an innovation that can edit our genetic makeup as if it were software application.
The program can crash or not work properly. CRISPR utilizes a similar idea however with our hereditary code. "Typos" in our genome can result in illness. CRISPR can correct these "typos." For several years, CRISPR was mostly a specific niche innovation that wasn't well understood. And during that time, there were really just 3 companies operating in this area. But things are changing. CRISPR is no longer simply theoretical. We're seeing actual results. We're treating illness and seeing that this innovation just works. And as a result, a "second crop" of early-stage CRISPR companies is going public and delivering extraordinary returns. This entire industry is successfully a greenfield opportunity.
There's room for numerous business to exist in this space. exponential tech investor. And there will be more. That's my prediction for CRISPR in 2021. I predict that two or 3 more hereditary editing business will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things occurring at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its newest Alpha, Fold software application can properly anticipate the folding of a protein based solely on its amino acid series with 92. 4% precision. That is essential since the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be efficient.
Historically, this has been a trial-and-error procedure. Now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're designed to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one but several drug treatments produced using this innovation. This was one of those breakthroughs that practically no one noticed. But it's going to have extensive ramifications for curing illness. And, of course, there will be lots of investment opportunities in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be shocked if it pulled back perhaps considerably prior to going greater. I've been covering bitcoin for a long time now. One of the first research study reports I ever released was on bitcoin - korean actress. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anybody who followed my suggestion. But at the time of that initial recommendation, I titled my report, "What's the Big Offer With Bitcoin?" That shows you where the discussion was at the time.
But no one is asking that question any longer. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. biotech stocks jeff brown. Mass, Mutual is a 150-year-old institution. So think of that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a huge reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another perk prediction In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown is worth about $27. 5 million and declares the details depends on date as of February 2021, however we might not separately validate this claim. Offered Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an accurate figure at this minute. Brown is best known for his sage-like capability to pick winning innovation stocks. He spent more than 25 years investigating innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience gives him an outstanding viewpoint on the marketplace. He's always on the hunt for brand-new chances, and he shares a lot of his best choices in the Near Future Report.
That's full marks, but it's not absurdly reasoned. Brown has an outstanding credibility as a stock-picker, and he effectively forecasted some of the biggest economic occasions of the past 20 years. Although he does not appear to launch his picks to the general public, the service's success is a direct indicator of Brown's stock-picking prowess. No one on Wall Street gets it ideal whenever, but Jeff Brown's precise forecasts have actually earned him legions of devoted followers. That states a lot about his capability. The Future Report is published by Brownstone Research study, a popular monetary research publisher. Brownstone Research provides a number of research study services with a variety of expertises - artificial intelligence.
The company is likewise connected with Bonner & Partners, another well-respected research study publisher - united states. On its site, Brownstone states its objective is to provide retail financiers with professional-grade research: "For too long, the finest financial investment research has not been available to individual investors. It has been generally booked for investment banks, hedge funds, personal equity, and high-net-worth customers. longtime readers. The objective of Brownstone Research study is to make that kind of exclusive research readily available to any investors looking to get an edge in the markets. The goal is easy to deliver distinct and rewarding financial investment research study discovered no place else." -Brownstone Research site excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also functions as the firm's Chief Investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to provide its clients. After years of constant success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a home name throughout the majority of America. If you understand even a little bit about the marketplace, you know that he has a credibility as a King Midas of sorts. biotech stocks. Everything he touches turns to gold! Jeff is aware of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next huge project.
In fact, Brown thinks S.A.V. melania trump. could be "the greatest trend of the 2020s, and he's not alone. Examine out these quotes from other widely known S.A.V. bulls: Elon's next big act will be marrying two innovative innovations: artificial intelligence and electrical cars. Musk hopes the mix will assist him establish the very first fully-autonomous, self-driving cars and trucks ever. It's nothing short of the automotive market's Holy Grail. As you understand, electrical cars and self-driving vehicle stocks have actually been big this year, however the Wall Street machine has approved buzz without much tangible outcome. Regardless of an extreme increase in competition over the past couple of years, Brown still believes Musk has the very best possibility of putting it all together.
tech could be the magic string that ties everything together. S.A.V. represents Shared Autonomous Automobile, and it could be the future of transport. Basically, this technology would enable you to rent your vehicle as a self-governing, self-driving taxi when you're not utilizing it. You merely get out of the cars and truck and press a button on an app that tells the car to "sign up with the fleet." Next thing you know, you're relaxing on your couch while your cars and truck shuttles ride-sharers around town. Most importantly, you get to keep a substantial chunk of the revenues. It sounds ridiculous, but it could be closed than you believe.